Active Surface Targeting for Precision Drug Delivery

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 2196 papers268 conceptsfrozen 2026-10-04

In traditional pharmacology, getting a drug to the right place is often a matter of "spray and pray." We rely on systemic circulation to carry molecules everywhere, hoping enough of the payload reaches the target before causing toxic side effects elsewhere. Even in early nanomedicine, accumulation in tumors was largely "passive," relying on the Enhanced Permeability and Retention (EPR) effect—the tendency of leaky tumor blood vessels to trap passing particles.

However, as Jinfeng Zhang and colleagues point out in Degradable Hollow Mesoporous Silicon/Carbon Nanoparticles, the EPR effect is often suboptimal and unpredictable. The research direction of Active Surface Targeting seeks to replace this passive drift with molecular "homing beacons." By decorating the surface of delivery vehicles with specific ligands, researchers are turning inert packages into smart agents that actively seek out and "dock" with specific cells.

The Ligand as a Molecular Key

The core intuition behind active targeting is the lock-and-key mechanism. Many diseased cells—whether they are cancerous, inflamed, or infected—overexpress specific proteins or sugars on their surfaces that healthy cells do not.

For example, Jianxu Li and his team discovered a tiny 17-amino acid peptide called odorranalectin. This peptide acts as a highly specific "key" for L-fucose, a sugar residue often found on cell surfaces. By attaching such small, low-toxicity peptides to a drug carrier, researchers can ensure the carrier only "sticks" to tissues where that specific sugar is prevalent.

This isn't just about sticking to the outside of a cell; it’s about tricking the cell into opening the door. As explained in Advanced nanomaterial for prostate cancer theranostics by Bin Hao, when a ligand binds to its corresponding receptor, it often triggers receptor-mediated endocytosis. The cell membrane wraps around the nanoparticle and pulls it inside, effectively concentrating the drug exactly where it is needed—inside the cytoplasm or even the nucleus.

Active targeting is particularly powerful when a drug must cross a "biological gauntlet," such as the Blood-Brain Barrier (BBB) or the harsh environment of the gastrointestinal tract.

  • The Brain: Hao Wu demonstrates in Polydopamine-based loaded temozolomide nanoparticles that functionalizing carriers with targeting ligands allows them to exploit natural transport pathways to cross the BBB. This overcomes the "cytoplasmic sequestration" that usually stops chemotherapy from reaching brain tumor DNA.
  • The Gut: For oral delivery of proteins like insulin, Shujun Cao and colleagues describe in Nanoparticles: Oral Delivery for Protein and Peptide Drugs how grafting ligands like RGD peptides or lectins allows particles to target specialized "M-cells" in the intestine, which then transport the cargo into the bloodstream.

Engineering the Delivery Vehicle

While early work focused on synthetic gold or silicon particles, the field is increasingly moving toward "bio-inspired" carriers like exosomes and viral capsids.

Mo Sha and others are engineering exosomes—nature’s own communication vesicles—by genetically modifying parent cells to produce vesicles that already display targeting antibodies on their surface. Similarly, in the realm of gene therapy, Huifang Peng highlights how engineering the viral protein shell (capsid) of Adeno-associated viruses (AAVs) can change their "tropism," or which organs they prefer to infect.

Redirecting the Body's Own Resources

Perhaps the most sophisticated evolution of this idea is not bringing a ligand from the lab, but recruiting one from the patient’s own blood.

In Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines, Yunxuan Feng and colleagues describe modifying nanoparticles with ligands that have a high affinity for albumin, the most abundant protein in our blood. By "hitching a ride" on albumin, these particles can be redirected away from the liver (where they might cause toxicity) and toward the lymphatic system, significantly boosting the effectiveness of mRNA vaccines.

Why It Works: The Shift in Perspective

The success of active surface targeting represents a fundamental shift in how we view drug delivery. We are moving away from treating the body as a series of plumbing pipes where flow and pressure dictate drug location. Instead, researchers like Yuling Xiao and Bin Zheng are treating the body as a complex information network. By using surface ligands to "address" the delivery vehicle, we ensure the therapeutic message is only read by the cells that need to hear it.

Papers in this version

Showing 60 of 196 papers.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 179 papers
  2. Version 1 · 2026-10-04 · 196 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_ligand_mediated_active_targeting_b7578cb7,
  title = {ligand-mediated active targeting},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/ligand-mediated-active-targeting/rdr_b7578cb73bd6439f955af14dfdd2e98e},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_active_surface_targeting_for_precision_d_b7578cb7_v1,
  title = {Active Surface Targeting for Precision Drug Delivery},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/active-surface-targeting-for-precision-drug-delivery/rdr_b7578cb73bd6439f955af14dfdd2e98e/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}